List view / Grid view
The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for certain metastatic colorectal cancers after a trial found the combination meaningfully improved response rates.
In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
The European Commission approval makes KEYTRUDA® (pembrolizumab) the first anti-PD-1 therapy approved for metastatic microsatellite instability-high (MSI-H) colorectal cancer patients in Europe.
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
A Phase I/IIa study has shown that arfolitixorin along with either irinotecan or oxaliplatin could shrink the size of tumours in colorectal cancer patients...
A key drug used to treat colorectal cancer could have more specific application using a test to show which patients would respond best to the treatment...
Watson for Clinical Trial Matching, an AI platform, has shown an increase of 80 percent in enrolment for breast cancer clinical trials, along with reduced screening times for patients...
Researchers find that vitamin D supplements could help to ease painful Irritable Bowel Syndrome symptoms...
Artemisinin, a potent anti-malarial drug, has been widely hailed as a promising alternative cancer treatment...
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
General study identifies targetable pathway that induces immunosuppressive environment in colorectal cancer...
In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months and caused fewer side effects...
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...
6 April 2017 | By Niamh Marriott, Junior Editor
BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead...
